ES2957742T3 - Métodos de tratamiento de los transtornos microvasculares autoinmunes - Google Patents

Métodos de tratamiento de los transtornos microvasculares autoinmunes Download PDF

Info

Publication number
ES2957742T3
ES2957742T3 ES18836058T ES18836058T ES2957742T3 ES 2957742 T3 ES2957742 T3 ES 2957742T3 ES 18836058 T ES18836058 T ES 18836058T ES 18836058 T ES18836058 T ES 18836058T ES 2957742 T3 ES2957742 T3 ES 2957742T3
Authority
ES
Spain
Prior art keywords
diosmetin
pharmaceutically acceptable
diosmin
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18836058T
Other languages
English (en)
Spanish (es)
Inventor
Robert Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRIMUS PHARMACEUTICALS Inc
Original Assignee
PRIMUS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRIMUS PHARMACEUTICALS Inc filed Critical PRIMUS PHARMACEUTICALS Inc
Application granted granted Critical
Publication of ES2957742T3 publication Critical patent/ES2957742T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18836058T 2017-07-19 2018-07-18 Métodos de tratamiento de los transtornos microvasculares autoinmunes Active ES2957742T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (1)

Publication Number Publication Date
ES2957742T3 true ES2957742T3 (es) 2024-01-24

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18836058T Active ES2957742T3 (es) 2017-07-19 2018-07-18 Métodos de tratamiento de los transtornos microvasculares autoinmunes

Country Status (12)

Country Link
US (2) US11278517B2 (https=)
EP (2) EP3654965B1 (https=)
JP (1) JP7237962B2 (https=)
KR (1) KR102717665B1 (https=)
CN (1) CN111065389B (https=)
AU (1) AU2018304208B2 (https=)
CA (1) CA3069921C (https=)
ES (1) ES2957742T3 (https=)
HR (1) HRP20231517T1 (https=)
MX (1) MX2020000625A (https=)
PL (1) PL3654965T3 (https=)
WO (1) WO2019018455A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法
WO2026014965A1 (ko) * 2024-07-11 2026-01-15 한국 한의학 연구원 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10596185B2 (en) 2014-03-31 2020-03-24 Ingredients By Nature Flavonoid compositions and uses thereof

Also Published As

Publication number Publication date
AU2018304208A1 (en) 2020-02-13
US11844777B2 (en) 2023-12-19
JP7237962B2 (ja) 2023-03-13
PL3654965T3 (pl) 2024-02-26
EP3654965A1 (en) 2020-05-27
CN111065389B (zh) 2023-11-21
KR20200051579A (ko) 2020-05-13
EP4269397A3 (en) 2024-01-31
WO2019018455A1 (en) 2019-01-24
US11278517B2 (en) 2022-03-22
KR102717665B1 (ko) 2024-10-14
EP3654965A4 (en) 2021-03-10
AU2018304208B2 (en) 2022-03-17
CA3069921A1 (en) 2019-01-24
JP2020528454A (ja) 2020-09-24
EP3654965C0 (en) 2023-09-06
EP3654965B1 (en) 2023-09-06
US20220168267A1 (en) 2022-06-02
HRP20231517T1 (hr) 2024-03-01
CA3069921C (en) 2022-01-18
US20200147031A1 (en) 2020-05-14
EP4269397A2 (en) 2023-11-01
MX2020000625A (es) 2020-09-28
CN111065389A (zh) 2020-04-24

Similar Documents

Publication Publication Date Title
ES2368299T3 (es) Uso de un beta-bloqueante para la fabricación de un medicamento para el tratamiento de hemangiomas.
ES2788548T3 (es) Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad
ES2363019T3 (es) Utilización de pirlindol para el tratamiento de las enfermedades que están caracterizadas por una proliferación de los linfocitos t y/o una hiperproliferación de queratinocitos en particular la dermatitis atópica y la psoriasis.
Vitiello et al. An update on the treatment of the cutaneous manifestations of systemic sclerosis: the dermatologist's point of view
EP3773543A1 (en) Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
ES2310262T3 (es) Regimen de dosificacion de bruprenorfina transdermica para analgesia.
ES2969469T3 (es) Método de tratamiento de afecciones relacionadas con el receptor de PGI2
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
ES2957742T3 (es) Métodos de tratamiento de los transtornos microvasculares autoinmunes
ES2402907T3 (es) Roscovitina para el tratamiento de ciertas enfermedades quísticas
ES2635353T3 (es) Formas de dosificación y usos terapéuticos de la L-4-cloroquinurenina
Torres et al. Treatment of generalized systemic sclerosis
WO2008120966A1 (es) Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.
JP2014141502A (ja) センタキンを用いた新規の治療方法
BR112021004542A2 (pt) inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos
ES2263591T3 (es) Uso de un preparado de combinacion en la terapia del cancer.
EP4157278A1 (en) Methods of treating pulmonary fibrosis
ES2988478T3 (es) Agente profiláctico y/o terapéutico para la demencia
RU2113805C1 (ru) Пищевая добавка янтавит
CN109641001A (zh) 用于治疗缺血性溃疡和伸展疤痕的组合物
TW202320772A (zh) 用於預防或治療全身性硬化症的醫藥組成物
ES2332884T3 (es) Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina.
ES2261772T3 (es) Uso de la propionil l-carnitina o de una de sus sales farmacologicamente aceptables para la preparacion de una medicina para el tratamiento de la enfermedad de la peyronie.
Elkady et al. Recent Modalities in Treatment of Atopic Dermatitis
IT202300010005A1 (it) Rutina per il trattamento dell’epidermolisi bollosa